AAPGAscentage Pharma Group Inc.Signing up patients
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Liposarcoma · Advanced Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 95 (planned)
- Started
- May 26, 2021
- Main results expected
- Apr 2026
- Fully finished
- Jan 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Limiting Toxicity (Phase I)
Measured over: 21 days
Recommended Phase II Dose
Measured over: 21 days
Overall Response Rate (Phase II)
Measured over: up to 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04785196 · record last updated 2025-02-26 · checked 2026-11-09 15:42 UTC